Results 61 to 70 of about 24,552 (280)

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Clinical feasibility of endovascular recanalization with intravascular ultrasound-guided wiring for chronic total occlusion of below-the-knee arteries

CVIR Endovascular, 2023
Background Revascularization with endovascular therapy (EVT) for complex below-the-knee (BTK) chronic total occlusion (CTO) remains a challenging problem.
Naoki Hayakawa, Satoshi Kodera, Hiromi Miwa, Shinya Ichihara, Satoshi Hirano, Masataka Arakawa, Yasunori Inoguchi, Shunichi Kushida   +7 more
doaj   +1 more source

Radial capacity and hemodynamics evaluation in vitro and implantable feasibility validation in vivo of thinner bioresorbable polymer vascular stents

BMEMat, EarlyView.
A series of in vitro experiments, numerical simulations and in vivo experiments were conducted to jointly evaluate the effects of different thicknesses of bioabsorbable polymer vascular stents on their radial capacity, hemodynamics and in vivo outcomes.
Chong Chen, Tao Li, Zhongyou Li, Jingyuan Zhou, Zhuo Zhang, Yan Xiong, Rifang Luo, Yu Chen, Yunbing Wang, Ping Fu   +9 more
wiley   +1 more source

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies

CPT: Pharmacometrics & Systems Pharmacology
The effectiveness of Bruton tyrosine kinase (BTK) inhibitors is influenced by the level of BTK occupancy in target tissues. In randomized phase 3 studies, progression‐free survival (PFS) with zanubrutinib was superior to ibrutinib, whereas acalabrutinib ...
Oleg Demin Jr, Ying Ou, Galina Kolesova, Dmitry Shchelokov, Alexander Stepanov, Veronika Musatova, Sri Sahasranaman, Yating Zhao, Xiangyu Liu, Zhiyu Tang, William D. Hanley   +10 more
doaj   +1 more source

Tetrazine Ligation in Living Systems: Beyond Fast Kinetics to Effective Bioorthogonality

Chemistry – A European Journal, EarlyView.
Rapid reaction kinetics (k2) alone do not ensure successful tetrazine ligation in living systems. This review introduces ‘effective orthogonality’—focusing on chemical survival, availability, and encounter—as a practical framework. We highlight how bottlenecks shift from cellular sinks to in vivo delivery limits, offering design strategies for reliable
Junhyeong Yim, Junyoung Park, Youngjun Lee, Jongmin Park   +3 more
wiley   +1 more source

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, EarlyView.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

The Relevance of Curative‐Intent Metastasectomy in Colorectal Cancer Patients: Real‐World Insights From a Certified Comprehensive Cancer Center in Germany

International Journal of Cancer, EarlyView.
Patients with metastatic colorectal cancer who are ineligible for upfront metastasectomy may still become candidates for secondary metastasectomy with curative intent following response to primary chemotherapy. However, most studies dichotomize metastatic colorectal cancer into resectable and unresectable disease.
Julian W. Holch, Jo‐Ann Eisenburger, Antony Weber, Iris Kammermeier‐Wehlau, Yannick Wiberg, Fabian Allmendinger, Kathrin Heinrich, Lena Weiss, C. Benedikt Westphalen, Victoria Krenmayr, Klara Dorman, Danmei Zhang, Theres Fey, Karin Berger‐Thürmel, Ulrich Wirth, Florian Kühn, Michael von Bergwelt‐Baildon, Jens Werner, Volker Heinemann   +18 more
wiley   +1 more source

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

Scientific Reports, 2017
BTK plays a critical role in the B cell receptor mediated inflammatory signaling in the rheumatoid arthritis (RA). Through a rational design approach we discovered a highly selective and potent BTK kinase inhibitor (CHMFL-BTK-11) which exerted its ...
Hong Wu, Qiong Huang, Ziping Qi, Yongfei Chen, Aoli Wang, Cheng Chen, Qianmao Liang, Jinghua Wang, Wensheng Chen, Jin Dong, Kailin Yu, Chen Hu, Wenchao Wang, Xiaochuan Liu, Yuanxin Deng, Li Wang, Beilei Wang, Xiaoxiang Li, Nathanael S. Gray, Jing Liu, Wei Wei, Qingsong Liu   +21 more
doaj   +1 more source

Releasing the brakes on BTK-targeting miRNA [PDF]

Blood, 2016
In this issue of Blood, Bottoni et al demonstrate that histone deacetylase (HDAC) inhibition promotes the upregulation of microRNAs (miRNAs or miRs) which target Bruton tyrosine kinase (BTK), subsequently suppressing prosurvival signaling in chronic lymphocytic leukemia (CLL) samples, and highlight a rationale for HDAC inhibitors in combination with ...
Matthew D. Blunt, Andrew J. Steele
openaire   +3 more sources

Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing N6‐Methyladenosine Methylation of Myc

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu, Jin‐Hao Chen, Yan‐Fang Wang, Xiao Wu, Hui‐Yun Ni, Qiu‐Rong Zhang   +5 more
wiley   +1 more source